ReviewFrontiers in immunology2024
Opportunities and challenges for anti-CD47 antibodies in hematological malignancies.
Review in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Review
- CD47 Aptamer-Decorated Fluorescent POSS Hybrid Nanoparticles as a Biohybrid Interface for Probing Prostate Cancer-Macrophage Interactions.Biomimetics (Basel, Switzerland) · 2026Article
- Targeting the CD47-SIRPα phagocytic checkpoint in cancer: Biology, translational opportunities, and next-generation therapeutic strategies.Smart molecules : open access · 2026Review
- GV1001 Reprograms CD47 Immune Checkpoint to Restore Macrophage Antitumor Activity in Oral Squamous Cell Carcinoma.International journal of molecular sciences · 2026Article
- CD47 stabilizes ROBO2 to regulate glioblastoma progression by preventing ITCH-mediated ubiquitination.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Fgl2-knockout tumor cells serve as a vaccine inducing long-duration brain-resident memory T cells that reject subsequent intracranial tumor cell challenges.Cancer letters · 2026Article
- Genetic risk classification in acute myeloid leukemia patients treated with hematopoietic cell transplantation and post-transplant cyclophosphamide.Haematologica · 2026Article
- The Dual Mechanism of Action of CO-005 Overcomes CD20 Resistance in Diffuse Large B-Cell Lymphoma.ImmunoTargets and therapy · 2026Article
- Review
- CD47 monoclonal antibodies differ in their capacity to induce immune response.European journal of microbiology & immunology · 2025Article
- The value of CD47 and CAP1 levels in early diagnosis and MACE prediction for patients with non-ST-segment elevation myocardial infarction.BMC cardiovascular disorders · 2025Article
- Development of a Novel Bifunctional Anti-CD47 Fusion Protein with Improved Efficacy and a Favorable Safety Profile.Molecular cancer therapeutics · 2025Article
- The Efficacy of Targeted Monoclonal IgA Antibodies Against Pancreatic Ductal Adenocarcinoma.Cells · 2025Article
- Targeting myeloid cells for hematological malignancies: the present and future.Biomarker research · 2025Review
- CD47-Targeted Therapy in Cancer Immunotherapy: At a Crossroads of Promise and Challenge.Oncology research · 2025Review
- SMAC mimetics induce human macrophages to phagocytose live cancer cells.Immunotherapy advances · 2025Article
- Expression of SIRPα-Fc by oncolytic virus enhances antitumor efficacy through tumor microenvironment reprogramming.Frontiers in immunology · 2025Article
- Therapeutic targeting of tumour-associated macrophage receptors.Immunotherapy advances · 2025Review
- A CD47 antibody with minimized erythrocyte and thrombocyte toxicities.Frontiers in oncology · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD47 is a cell-surface ligand that is overexpressed in various malignancies and that binds to SIRPα on macrophages to promote tumor cell evasion of phagocytosis. Blocking the CD47-SIRPα axis can increase the phagocytosis of macrophages to exert antitumor effects. CD47-based immunotherapy is a current research focus. The combination of anti-CD47 antibodies with other drugs has shown encouraging response rates in patients with hematological tumors, but side effects also occur. Bispecific antibodies and SIRPα/Fc fusion proteins appear to balance the efficacy and safety of treatment. We review the latest clinical research advances and discuss the opportunities and challenges associated with CD47-based immunotherapy for hematological malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.